Jaguar Health, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company that develops and commercializes novel, plant-based, non-opioid prescription medicines derived from rainforest plants for gastrointestinal distress in people and animals, including chronic debilitating diarrhea, urgency, incontinence, and cramping; it operates through Human Health and Animal Health segments targeting companion animals, production animals, HIV/AIDS patients on antiretroviral therapy, and cancer patients. The company offers Mytesi (crofelemer 125 mg delayed-release tablets), an FDA-approved anti-secretory antidiarrheal for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; Canalevia-CA1 (crofelemer delayed-release tablets), an FDA-conditionally approved prescription product for chemotherapy-induced diarrhea in dogs; and Neonorm products for calves and foals; its pipeline includes crofelemer in Phase III trials for prophylaxis of cancer therapy-related diarrhea (OnTarget trial topline results expected forthcoming) and Phase II/III for rare diseases such as short bowel syndrome and microvillus inclusion disease, as well as irritable bowel syndrome, idiopathic diarrhea, and NP-300 in Phase I for moderate-to-severe diarrhea. Founded in 2013 and headquartered in San Francisco, California, Jaguar conducts operations primarily in the United States with expansion efforts in Europe via Napo Therapeutics, an Italian subsidiary established in 2021, and supports investigator-initiated studies in the US, EU, and Middle East/North Africa; it maintains strategic relationships including a joint venture, Magdalena Biosciences, with Filament Health for mental health indications, an exclusive distribution agreement for Gelclair, and recent financial activities such as a $1.5 million registered direct offering in May 2025 and a submission to the European Medicines Agency in December 2025 regarding an EU approval pathway for Canalevia.
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Jaguar Health Compliant with Nasdaq Bid Price Rule
Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health Reports First Quarter 2026 Financials
Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
Jaguar Health Stock Surges On FDA Breakthrough Discussions For Rare Disease Therapy
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
Jaguar Health, Inc. (JAGX) Q4 2025 Earnings Call Prepared Remarks Transcript
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health Reports 2025 Financials
Head to Head Review: Jaguar Animal Health (NASDAQ:JAGX) and Telomir Pharmaceuticals (NASDAQ:TELO)